@BioWorld featured non-clinical data Promontory Therapeutics presented at #ENASymp22 on PT-112’s immunogenic cell death-inducing effects on human prostate cancer cell mitochondria: https://t.co/QynwkKI6QA #biotech#biopharma#cancerresearch
@PromontoryTx, developers of novel small-molecule anti-cancer agents that promote adaptive immune responses, is our "Cancer Immunology Solution of the Year" winner! https://t.co/IuvKchgRul #BioTechBreakthrough#cancerresearch
Promontory Therapeutics CMO, Dr. Johan Baeck, and SVP of Research + Development, Dr. Tyler Ames, are attending the 29th Annual @PCFnews Scientific Retreat in Carlsbad, CA. Learn more about PCF here: https://t.co/NkmcSJ567Z
#PCFRetreat22#biotech#biopharma#prostatecancer
Promontory Therapeutics presented data showing new
non-clinical data on its lead candidate, immunogenic cell death inducer PT-112, and its effects on
human prostate cancer cell mitochondria at #ENASymp22. Learn more here: https://t.co/1eYKBslsCM #biopharma#cancerresearch
Promontory Therapeutics announced today that it has received a U.S. patent for therapeutic applications of lead agent PT-112 as an immuno-modulatory agent. Learn more here: https://t.co/S7VlQex5wS
#biotech#biopharma#cancerresearch
Promontory Therapeutics will present data on PT-112’s effects on prostate cancer cell mitochondria at #ENASymp22. Learn more here: https://t.co/j9DhqiywKf
#biotech#biopharma#cancerresearch
Meet the 2022 Notable Health Care Leaders. The 86 professionals named as this year's Notable Health Care Leaders are recognized for their consummate leadership, pioneering accomplishments and ability to adjust to crises—including Covid-19 https://t.co/VLL33gm2nK
Congratulations Robert! Promontory co-founder & CEO Robert Fallon has been named a @CrainsNewYork 2022 Notable Healthcare Leader. Crain’s recaps his career and company leadership: https://t.co/S5YO93gOVR #biotech#biopharma#cancerresearch
Promising mechanistic data from Promontory Therapeutics’ lead therapeutic candidate PT-112 is published in the latest, peer-reviewed issue of @Cancers_MDPI. Learn more: https://t.co/tJNDOhmdGT
#mdpicancers
Promontory Therapeutics co-founder & COO @mpricenyc gives @FiercePharma’s “Top Line” podcast his thoughts on how it felt to be back in-person at #ASCO22. Tune in here: https://t.co/hwdoOCnxGn
Promontory Therapeutics co-founder & COO @mpricenyc details the company’s progress in a story from @FierceBiotech’s @GabrielleMasso9 for her coverage of #ASCO22. Read the full story, including recently published data, here: https://t.co/WNZrztYGXl
Promontory Therapeutics co-founder & COO @mpricenyc gave @FierceBiotech his account of the “new normal” at this year’s in-person #ASCO22. Read @GabrielleMasso9’s story here: https://t.co/zR6d7x5PpX
Promising data from Promontory Therapeutics’ Phase 1 study of lead therapeutic candidate PT-112 now published in the peer-review journal eClinicalMedicine of @TheLancet. Learn more: https://t.co/YXXpju7NNK
Promontory Therapeutics CEO Robert Fallon explains the importance of the Biden Administration’s Cancer Moonshot initiative in a piece he penned for @medcitynews. Read here: https://t.co/3fAxGXa5U9
Promontory Therapeutics is honored to announce the appointment of Jounce Therapeutics + Novartis veteran, Dr. Johan Baeck, as Executive Vice President and Chief Medical Officer. Read more here: https://t.co/6rtVaGDbhl #biotech
Congratulations Matthew! Promontory co-founder & COO @mpricenyc has been named a @PharmExec 2022 Emerging Pharma Leader. Pharma Exec profiles his career, company leadership, and drive to help patients with cancer here: https://t.co/B3TQ6kH7aY #biotech#biopharma#cancerresearch
We are excited to announce that Phosplatin is now Promontory Therapeutics! New name, new logo, same team dedicated to the same mission: advancing small molecule immunotherapies to extend and improve the quality of life for cancer patients. https://t.co/sWH46dKDn1